CryoPort (CYRX)
Market Price (12/30/2025): $9.535 | Market Cap: $477.9 MilSector: Industrials | Industry: Air Freight & Logistics
CryoPort (CYRX)
Market Price (12/30/2025): $9.535Market Cap: $477.9 MilSector: IndustrialsIndustry: Air Freight & Logistics
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 14%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 10.0% | Weak multi-year price returns2Y Excs Rtn is -86%, 3Y Excs Rtn is -122% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -51 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% | |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 41% | Key risksCYRX key risks include [1] severe financial underperformance, Show more. | |
| Megatrend and thematic driversMegatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 14%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 10.0% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 41% |
| Megatrend and thematic driversMegatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support. |
| Weak multi-year price returns2Y Excs Rtn is -86%, 3Y Excs Rtn is -122% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -51 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% |
| Key risksCYRX key risks include [1] severe financial underperformance, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
In the approximate time period from August 31, 2025, to December 30, 2025, CryoPort (CYRX) experienced several key developments that contributed to its stock movement.
1. CryoPort reported stronger-than-expected third-quarter 2025 financial results. On November 4, 2025, the company announced a narrower loss per share and revenues of $44.2 million, surpassing analyst estimates by $2.98 million.
2. The company provided an updated 2025 revenue outlook and highlighted significant growth in its Life Sciences segments. CryoPort updated its full-year 2025 revenue guidance to a range of $170 million to $174 million. This was supported by a reported 36% year-over-year growth in revenue from its support of commercial cell and gene therapy, demonstrating strong performance in a key sector.
Show more
1. CryoPort reported stronger-than-expected third-quarter 2025 financial results. On November 4, 2025, the company announced a narrower loss per share and revenues of $44.2 million, surpassing analyst estimates by $2.98 million.
2. The company provided an updated 2025 revenue outlook and highlighted significant growth in its Life Sciences segments. CryoPort updated its full-year 2025 revenue guidance to a range of $170 million to $174 million. This was supported by a reported 36% year-over-year growth in revenue from its support of commercial cell and gene therapy, demonstrating strong performance in a key sector.
Show more
Stock Movement Drivers
Fundamental Drivers
The 1.5% change in CYRX stock from 9/29/2025 to 12/29/2025 was primarily driven by a 12.8% change in the company's P/E Multiple.| 9292025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.41 | 9.55 | 1.49% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 237.88 | 243.79 | 2.49% |
| Net Income Margin (%) | 31.67% | 27.72% | -12.46% |
| P/E Multiple | 6.28 | 7.08 | 12.83% |
| Shares Outstanding (Mil) | 50.26 | 50.13 | 0.26% |
| Cumulative Contribution | 1.49% |
Market Drivers
9/29/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| CYRX | 1.5% | |
| Market (SPY) | 3.6% | 31.8% |
| Sector (XLI) | 2.5% | 28.6% |
Fundamental Drivers
The 28.0% change in CYRX stock from 6/30/2025 to 12/29/2025 was primarily driven by a 22.3% change in the company's P/S Multiple.| 6302025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.46 | 9.55 | 28.02% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 232.13 | 243.79 | 5.02% |
| P/S Multiple | 1.61 | 1.96 | 22.33% |
| Shares Outstanding (Mil) | 49.95 | 50.13 | -0.36% |
| Cumulative Contribution | 28.01% |
Market Drivers
6/30/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| CYRX | 28.0% | |
| Market (SPY) | 11.6% | 24.2% |
| Sector (XLI) | 6.8% | 24.3% |
Fundamental Drivers
The 22.4% change in CYRX stock from 12/29/2024 to 12/29/2025 was primarily driven by a 41.3% change in the company's Total Revenues ($ Mil).| 12292024 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.80 | 9.55 | 22.44% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 172.58 | 243.79 | 41.27% |
| P/S Multiple | 2.23 | 1.96 | -12.09% |
| Shares Outstanding (Mil) | 49.42 | 50.13 | -1.43% |
| Cumulative Contribution | 22.41% |
Market Drivers
12/29/2024 to 12/29/2025| Return | Correlation | |
|---|---|---|
| CYRX | 22.4% | |
| Market (SPY) | 16.6% | 30.3% |
| Sector (XLI) | 18.9% | 28.8% |
Fundamental Drivers
The -45.0% change in CYRX stock from 12/30/2022 to 12/29/2025 was primarily driven by a -45.6% change in the company's P/S Multiple.| 12302022 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 17.35 | 9.55 | -44.96% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 233.36 | 243.79 | 4.47% |
| P/S Multiple | 3.61 | 1.96 | -45.57% |
| Shares Outstanding (Mil) | 48.52 | 50.13 | -3.31% |
| Cumulative Contribution | -45.02% |
Market Drivers
12/30/2023 to 12/29/2025| Return | Correlation | |
|---|---|---|
| CYRX | -38.3% | |
| Market (SPY) | 47.9% | 29.8% |
| Sector (XLI) | 41.1% | 31.4% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CYRX Return | 167% | 35% | -71% | -11% | -50% | 24% | -41% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 151% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| CYRX Win Rate | 67% | 50% | 42% | 33% | 50% | 58% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| CYRX Max Drawdown | -18% | 0% | -73% | -47% | -64% | -40% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See CYRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/29/2025 (YTD)
How Low Can It Go
| Event | CYRX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -89.0% | -25.4% |
| % Gain to Breakeven | 808.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -31.4% | -33.9% |
| % Gain to Breakeven | 45.8% | 51.3% |
| Time to Breakeven | 44 days | 148 days |
| 2018 Correction | ||
| % Loss | -48.6% | -19.8% |
| % Gain to Breakeven | 94.5% | 24.7% |
| Time to Breakeven | 71 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -75.9% | -56.8% |
| % Gain to Breakeven | 315.2% | 131.3% |
| Time to Breakeven | 371 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
CryoPort's stock fell -89.0% during the 2022 Inflation Shock from a high on 11/4/2021. A -89.0% loss requires a 808.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
AI Analysis | Feedback
- FedEx for ultra-cold biopharma shipments.
- AWS for advanced therapy cold chain.
AI Analysis | Feedback
- Cryoport Express® Cold Chain Logistics: This service provides integrated, validated logistics for temperature-sensitive biological materials, including advanced therapies, using specialized cryogenic shipping containers and real-time monitoring across a global network.
- MVE Biological Solutions Cryogenic Equipment: Manufactures and supplies stainless steel cryogenic storage equipment, such as dewars and freezers, for long-term preservation of biological materials and industrial gas applications.
AI Analysis | Feedback
CryoPort (formerly traded under the symbol CYRX, now part of V-shaped Life Sciences under VCYT) primarily sells its services to other companies, operating on a business-to-business (B2B) model. Based on its public filings (such as 10-K reports prior to its merger and rebranding), CryoPort did not report any single customer accounting for 10% or more of its total revenue. Therefore, specific company names for major customers are not disclosed. However, CryoPort's major customers can be categorized by the types of companies and institutions they serve within the life sciences industry, particularly those requiring advanced cold chain logistics for temperature-sensitive biological materials, including cell and gene therapies. These include:- Pharmaceutical Companies: Large and small pharmaceutical companies developing and commercializing drugs, especially biologics and advanced therapeutic medicinal products (ATMPs), which require precise temperature control during storage and transport for clinical trials and commercial distribution.
- Biotechnology Companies: Firms specializing in biotechnology research and development, particularly those involved in novel therapies like cell, gene, and immunotherapies, which rely heavily on ultra-low temperature cryogenic logistics for their critical materials and products.
- Contract Research Organizations (CROs): Companies that provide outsourced research services to the pharmaceutical, biotechnology, and medical device industries. CROs often manage clinical trials that involve the transport of highly sensitive biological samples and therapies, utilizing CryoPort's specialized cold chain solutions.
- Academic and Research Institutions: Universities, research laboratories, and hospitals involved in cutting-edge biological research, clinical studies, and the development of new therapies often require secure and compliant cryogenic transport for their research materials and patient samples.
- Healthcare Providers: Hospitals, specialized clinics, and other healthcare facilities that administer advanced therapies to patients, requiring reliable and safe transport of these delicate products from manufacturing sites to the point of care.
AI Analysis | Feedback
- FedEx Corporation (Symbol: FDX)
- United Parcel Service, Inc. (Symbol: UPS)
- Deutsche Post AG (operating DHL Express) (Symbol: DPW.DE / DPSGY)
- AmerisourceBergen Corporation (operating World Courier) (Symbol: ABC)
AI Analysis | Feedback
Jerrell W. Shelton, President and Chief Executive Officer, Chairman
Jerrell Shelton has over 40 years of executive and corporate governance experience across various industries, including information services, software, telecommunications, manufacturing, natural resources, and distribution. He joined Cryoport's board in October 2012 and was appointed President and CEO in November 2012, becoming Chairman of the Board in October 2015. Prior to Cryoport, he served as President and CEO of several companies, including NDC Holdings, Continental Graphics Holdings, Thomson Business Information Group, and Advantage Companies. Under his leadership, these companies achieved rapid revenue growth, improved profitability, and increased shareholder value. He was also a visiting executive at IBM Research, where he contributed to the creation and development of WebFountain.
Robert S. Stefanovich, Chief Financial Officer and Treasurer
Robert Stefanovich possesses more than 30 years of experience in financial management and strategy, including over 20 years as CFO in the specialty pharma, medical device, and software sectors. He has served as CFO for Novalar Pharmaceuticals, a venture-backed specialty pharmaceutical company, and as CFO for three publicly traded companies: Xcorporeal (a medical device company), Artemis International Solutions Corporation (a software company), and Aethlon Medical (a medical device company). Earlier in his career, he was Vice President of Administration at SAIC.
Mark W. Sawicki, Ph.D., Chief Scientific Officer
Dr. Mark Sawicki has over 20 years of executive and sales management experience, consistently achieving corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Before his current role, he was the chief business officer at Alcami and held senior business development positions at AGC Biologics and Curia, where he significantly increased revenue. He also served as President and Chief Executive Officer of Cryoport Systems, LLC, and Chief Commercial Officer at Cryoport Systems.
Tony Ippolito, Vice President, General Counsel and Corporate Secretary
Tony Ippolito has more than 18 years of experience in mergers and acquisitions, securities law, and general corporate law. Prior to joining Cryoport, he was a partner in the Corporate and Securities practice group at Snell & Wilmer, LLP, where he advised reporting companies on securities law matters, M&A, private placements, venture capital financings, and owner buyouts.
Kylie Crowe, Vice President, Global Human Resources & Organizational Development
Kylie Crowe has over 20 years of experience in Human Resources, with more than 15 years as a global senior-level HR executive in the clinical research, medical devices, and healthcare industries. Before joining Cryoport, she was the Global HR Director at Covance Inc.
AI Analysis | Feedback
The public company CryoPort (CYRX) faces several key business risks, primarily stemming from its financial performance, the highly competitive nature of its specialized market, and the stringent regulatory environment in which it operates. Here are the key risks identified: 1. Financial Performance and Profitability ChallengesCryoPort has demonstrated significant financial challenges, including a substantial decline in market capitalization and enterprise value. The company has reported a negative profit margin of -50.17% and a negative operating margin of -38.98%, indicating that its expenses significantly outweigh its earnings. Revenue has also declined by 13.10% year-over-year, with a net income deeply in the negative at -$120.91 million. Although CryoPort maintains a cash surplus, it also carries substantial debt. Concerns have been raised regarding management's decisions, such as share buybacks, amidst ongoing losses and modest revenue growth projections, which could hinder the company's ability to achieve consistent positive cash flows. 2. Intensifying Competition and Market Dynamics Shift
CryoPort operates in a dynamic and highly competitive biopharma cold chain logistics sector. While it holds a dominant market share of approximately 70-75% in clinical trial logistics for cell and gene therapies, it faces formidable competition from specialized logistics rivals like Marken and World Courier, as well as general shipping giants such as DHL and FedEx. The industry's pivot towards allogeneic therapies, which necessitates a large-scale commercial distribution network, directly pits CryoPort against these larger logistics entities that possess more extensive global networks and different economies of scale. Strategic alliances and technological advancements by competitors are continually reshaping the market and could challenge CryoPort's integrated model and its established position. 3. Strict Regulatory and Compliance Landscape
Operating in the life sciences sector, particularly with sensitive biological materials like cell and gene therapies, exposes CryoPort to a highly stringent regulatory environment. Adherence to strict regulatory and quality parameters is critical, as even minor oversights can lead to significant regulatory delays, product loss, or compromised patient safety. Specific risks include the need for validated shipping lanes, comprehensive documentation for packaging qualifications, consistent regulatory practices, and readily available pre-qualified backup shipping systems. Non-compliance with regulations such as FDA Good Distribution Practices (GDP), WHO temperature monitoring standards, and International Air Transport Association (IATA) regulations can result in substantial financial penalties and reputational damage. The potential product loss from temperature deviations alone can range from $3.5 million to $7.2 million per advanced therapy shipment.
AI Analysis | Feedback
The clear emerging threat to CryoPort (CYRX) is the increasing investment and aggressive expansion by larger, integrated global logistics providers (such as UPS Healthcare/Marken, FedEx Healthcare, and DHL Life Sciences) into the highly specialized ultra-cold chain logistics market for cell and gene therapies. These companies are leveraging their immense resources, existing global networks, and comprehensive logistics infrastructure to develop and offer services that directly compete with CryoPort's niche, potentially eroding its market share and pricing power over time as they enhance their specialized capabilities in this high-growth sector.
AI Analysis | Feedback
Cryoport Inc. (CYRX) provides integrated temperature-controlled supply chain solutions for the life sciences industry, primarily serving the biopharma/pharmaceutical, animal health, and human reproductive medicine markets globally. Their main offerings include logistics management (shipping and transportation), cryopreservation services, bioservices such as biostorage, and the manufacturing of cryogenic systems. The addressable markets for Cryoport's main products and services are as follows: * Cell and Gene Therapy Cold Chain Logistics: The global cell and gene therapy cold chain logistics market was valued at approximately USD 1.89 billion in 2024, is projected to reach around USD 2.19 billion in 2025, and is expected to grow to approximately USD 8.06 billion by 2034. North America held approximately a 44% share of this market in 2024. * Biopharma Cold Chain Logistics: The global biopharma cold chain logistics market size was valued at USD 18.23 billion in 2024 and is anticipated to grow to USD 51.58 billion by 2034, with a compound annual growth rate (CAGR) of 10.98% from 2025 to 2034. Another estimate placed the global market size for cold-chain logistics for biopharma at $22.8 billion in 2024. North America accounted for the largest revenue share in this market in 2024. * Reproductive Medicine Cold Chain Logistics: Cryoport supports the human reproductive market globally, which primarily involves In-Vitro Fertilization (IVF) support for patients and fertility clinics. However, a specific global or regional market size for reproductive medicine *cold chain logistics* was not identified in the provided search results. * Animal Health Cold Chain Logistics: Cryoport also supports the global animal health market, encompassing animal husbandry, companion animals, and recreational animal health. A specific global or regional market size for animal health *cold chain logistics* was not identified in the provided search results. Given the information above, specific market sizes for Reproductive Medicine Cold Chain Logistics and Animal Health Cold Chain Logistics are not available in the provided search results. Therefore, for these two categories, the market size is null.null
AI Analysis | Feedback
CryoPort (symbol: CYRX) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:- Growth in Commercial Cell and Gene Therapies: CryoPort continues to experience significant revenue growth from its support of commercial cell and gene therapies, with a 36% year-over-year increase in Q3 2025 alone. As a pure-play end-to-end temperature-controlled supply chain platform, CryoPort is positioned to benefit from the ongoing global adaptation and increasing number of these life-saving therapies reaching commercialization. This segment is anticipated to be a primary driver of growth for years to come.
- Expansion of Life Sciences Services, particularly BioStorage/BioServices: The Life Sciences Services segment, which includes BioStorage/BioServices, has demonstrated consistent double-digit growth, with a 16% year-over-year increase in Q3 2025 and a 21% rise in BioStorage/BioServices revenue. This growth is attributed to the persistent demand for CryoPort's integrated platform, the introduction of expanded capabilities to existing customers, and the addition of new clients to its global network.
- Increasing Portfolio of Clinical Trials Progressing to Commercialization: CryoPort supports a substantial and growing number of global clinical trials in regenerative medicine, including 745 active clinical trials as of Q3 2025, with 83 of them in Phase 3. This extensive clinical trials pipeline represents a significant long-term revenue growth opportunity as more therapies advance through the clinical stages and gain regulatory approvals to become commercial therapies. For 2025, the company anticipates up to 23 additional application filings, five new therapy approvals, and five approvals for label/geographic expansions or moves to earlier lines of treatment.
- Launch of New and Advanced Life Sciences Products: CryoPort's Life Sciences Products segment also contributes to revenue growth, with a 15% year-over-year increase in Q3 2025. This is driven by improved demand for its cryogenic systems and the strategic launch of new products. For example, in Q3 2025, CryoPort expanded its product portfolio with the introduction of the MVE Biological Solutions next-generation SC4/2V and SC4/3V vapor shippers, which feature innovative technologies for enhanced protection and integrated condition monitoring.
- Strategic Partnerships and Global Infrastructure Expansion: CryoPort is actively expanding its global footprint and enhancing service delivery through strategic initiatives. The company's strategic partnership with DHL Group is expected to strengthen its positioning in the EMEA and APAC regions. Additionally, CryoPort has been expanding its global infrastructure, including the opening of the logistics portion of its new global supply chain center at Charles de Gaulle Airport in Paris and onboarding clients for IntegriCell in Belgium and Houston. These expansions aim to better serve clients and diversify revenue streams.
AI Analysis | Feedback
Share Repurchases
- Cryoport authorized a repurchase program on March 11, 2022, to purchase up to $100.0 million in common stock and/or convertible senior notes through December 31, 2025.
- During 2022, $37.9 million was spent to repurchase 1,604,994 shares of common stock under this program.
- On August 6, 2024, a new $200 million repurchase program was authorized, and the company repurchased $160 million in aggregate principal amount of its 0.75% Convertible Senior Notes due in 2026 for $141.6 million.
Share Issuance
- In January 2021, Cryoport completed a public offering of 4,356,059 shares of common stock at $66.00 per share, resulting in gross proceeds of approximately $287.5 million and net proceeds of approximately $234.5 million, intended for general corporate purposes and infrastructure expansion.
- In October 2020, Cryoport issued $25 million of common stock in a private placement to funds affiliated with The Blackstone Group Inc. in conjunction with the MVE Biological Solutions acquisition.
Inbound Investments
- In October 2020, funds affiliated with The Blackstone Group Inc. invested $250 million in newly designated Series C Convertible Preferred Stock in Cryoport.
Outbound Investments
- In October 2020, Cryoport acquired MVE Biological Solutions and CRYOPDP. The CRYOPDP acquisition was for approximately €49 million (reported as under $57 million).
- In April 2021, Cryoport acquired Critical Transport Solutions Australia Pty Ltd (CTSA) for approximately $5 million, integrating it into its CRYOPDP business unit.
- In March 2025, Cryoport announced a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP from Cryoport for an enterprise valuation of $195 million.
Capital Expenditures
- Capital expenditures for the second quarter of 2025 were $4.4 million.
- Cryoport has opened a new global supply chain center at Charles de Gaulle Airport in Paris.
- The company plans to open another Global Supply Chain Center in Santa Ana, California, in the second half of 2026, consolidating three existing locations and featuring next-generation technology.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CYRX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11212025 | CNM | Core & Main | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 18.3% | 18.3% | -1.6% |
| 11212025 | VRRM | Verra Mobility | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 5.5% | 5.5% | -1.2% |
| 11212025 | LII | Lennox International | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | 0.0% |
| 11212025 | ADP | Automatic Data Processing | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 2.9% | 2.9% | -1.2% |
| 11212025 | CW | Curtiss-Wright | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 5.7% | 5.7% | -0.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for CryoPort
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.06 |
| Mkt Cap | 159.0 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 159.0 |
| P/S | 3.2 |
| P/EBIT | 21.1 |
| P/E | 33.0 |
| P/CFO | 16.1 |
| Total Yield | 5.2% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.4 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.8% |
| 3M Rtn | 4.6% |
| 6M Rtn | 16.9% |
| 12M Rtn | 18.9% |
| 3Y Rtn | 72.0% |
| 1M Excs Rtn | -1.2% |
| 3M Excs Rtn | 0.9% |
| 6M Excs Rtn | 5.6% |
| 12M Excs Rtn | 3.4% |
| 3Y Excs Rtn | -5.1% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $9.55 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -11.2% | |
| 50 Days | 200 Days | |
| DMA Price | $9.37 | $7.91 |
| DMA Trend | up | down |
| Distance from DMA | 2.0% | 20.7% |
| 3M | 1YR | |
| Volatility | 56.7% | 99.7% |
| Downside Capture | 113.82 | 155.53 |
| Upside Capture | 101.22 | 152.45 |
| Correlation (SPY) | 31.9% | 30.3% |
CYRX Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.58 | 1.46 | 1.39 | 1.91 | 1.52 | 1.83 |
| Up Beta | 3.92 | 2.84 | 2.86 | 3.34 | 1.34 | 1.81 |
| Down Beta | -0.40 | 1.50 | 1.46 | 1.32 | 1.76 | 1.85 |
| Up Capture | 185% | 100% | 105% | 242% | 228% | 416% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 9 | 20 | 28 | 55 | 108 | 344 |
| Down Capture | 91% | 105% | 89% | 122% | 124% | 111% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 10 | 21 | 34 | 69 | 139 | 402 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of CYRX With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| CYRX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 24.2% | 19.1% | 16.7% | 65.4% | 7.5% | 4.2% | -7.3% |
| Annualized Volatility | 99.0% | 18.8% | 19.4% | 19.8% | 15.3% | 17.0% | 34.9% |
| Sharpe Ratio | 0.64 | 0.79 | 0.67 | 2.43 | 0.27 | 0.08 | -0.06 |
| Correlation With Other Assets | 28.9% | 30.4% | 3.6% | 9.2% | 22.5% | 32.6% | |
ETFs used for asset classes: Sector ETF = XLI, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of CYRX With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| CYRX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -28.0% | 13.8% | 14.8% | 17.7% | 11.2% | 5.1% | 30.2% |
| Annualized Volatility | 79.2% | 17.2% | 17.1% | 15.6% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | -0.07 | 0.64 | 0.70 | 0.91 | 0.48 | 0.18 | 0.57 |
| Correlation With Other Assets | 36.3% | 41.0% | 6.4% | 7.4% | 36.7% | 20.5% | |
ETFs used for asset classes: Sector ETF = XLI, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of CYRX With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| CYRX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 16.8% | 13.7% | 15.0% | 14.6% | 6.9% | 5.4% | 69.0% |
| Annualized Volatility | 76.3% | 19.9% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.55 | 0.61 | 0.72 | 0.82 | 0.31 | 0.23 | 0.89 |
| Correlation With Other Assets | 25.9% | 31.8% | 3.4% | 6.8% | 25.0% | 11.6% | |
ETFs used for asset classes: Sector ETF = XLI, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2025 | -7.5% | -4.0% | 3.5% |
| 8/6/2025 | -6.3% | 3.8% | 18.3% |
| 3/4/2025 | 30.6% | 31.4% | 21.7% |
| 11/7/2024 | -3.6% | -8.0% | 3.9% |
| 8/6/2024 | -0.3% | 5.3% | 5.4% |
| 3/12/2024 | -11.9% | 1.5% | 10.8% |
| 11/8/2023 | 10.0% | 29.5% | 48.3% |
| 8/9/2023 | -1.8% | -4.6% | -6.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 11 |
| # Negative | 11 | 10 | 10 |
| Median Positive | 7.7% | 5.3% | 10.8% |
| Median Negative | -3.6% | -7.4% | -7.9% |
| Max Positive | 30.6% | 39.4% | 54.9% |
| Max Negative | -32.0% | -24.1% | -31.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/12/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/08/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/07/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/07/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/08/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/08/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 03/13/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/09/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/09/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/04/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 02/28/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/04/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/04/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/05/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 02/28/2022 | 10-K (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.